Nektar Therapeutics (NKTR)
100.78
+15.92
(+18.76%)
USD |
NASDAQ |
Apr 20, 09:51
Nektar Therapeutics SG&A Expense (Quarterly) : 11.18M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Boston Scientific Corp. | 1.834B |
| Soleno Therapeutics, Inc. | 40.88M |
| Eli Lilly & Co. | 3.132B |
| Regeneron Pharmaceuticals, Inc. | 775.00M |
| Esperion Therapeutics, Inc. | 41.43M |